Graphs Built From Reported Results

ITP: Immune dysregulation ↔ Platelet production — Visual evidence

Visuals first — two interactive figures that summarize quantitative evidence for production vs destruction and a mechanistic Sankey showing immune pathways linking to platelet loss or impaired production. Explanatory notes and citations follow each figure. (More mechanistic references beneath.)

Figure 1: Historical platelet turnover studies pooled in a narrative review show that a substantial fraction of patients have evidence consistent with impaired platelet production (84/218) while others show increased platelet destruction (45/218) and many are intermediate/normal (89/218) — supporting a mixed-pathogenesis model where production defects matter clinically BJH 2009 ITP turnover

Figure 2: Sankey representation mapping key immune actors (autoantibodies, FcγR+ phagocytes, cytotoxic T cells, TFH/B-cell axis, Treg defects) to two clinical endpoints — peripheral platelet clearance and impaired megakaryocyte/platelet production. Widths are schematic but sized to reflect relative mechanistic emphasis evidenced in literature: autoantibodies → FcγR phagocytosis (strong), autoantibodies/TFH→ impaired MK maturation (substantial), Treg deficits → amplifying both arms via loss of regulation Autoimmunity Reviews ITP Pathogenesis

Key mechanistic evidence (selected primary findings)

• Autoantibodies inhibit megakaryopoiesis: Multiple in vitro studies show ITP plasma and monoclonal anti‑GPIb or anti‑GPIIb/IIIa antibodies reduce megakaryocyte yield and maturation — supporting a production defect mediated by humoral immunity Chang et al. Blood 2003
• Clinical response to TPO‑receptor agonists: Efficacy of TPO‑RAs (eltrombopag, romiplostim) in chronic ITP implies a clinically meaningful production limitation in many patients; this observation converges with in vitro suppression data BJH 2009 TPO-RA evidence
• Immunomodulatory cell therapies & MSCs: Umbilical-cord MSCs suppress autoreactive lymphocytes, increase Tregs, reduce anti‑platelet IgG in cultures, and improved platelet production in vitro and in two refractory patient case reports — suggesting modulation of immune dysregulation can restore MK function UC-MSC ITP study
• Genetic immune dysregulation informs refractory cytopenias: Pediatric series using genetic testing found monogenic immune dysregulation disorders that guided targeted therapy (JAK inhibitors, abatacept, rapamycin) and led to remissions in many cases — demonstrating that upstream immune defects can underlie refractory ITP-like presentations Haematologica 2026 genetic-guided therapy
• Splicing / Treg induction axis in ITP: Emerging work implicates splicing factor SRSF1 regulating LCK exon 8 inclusion; reduced SRSF1 → exon skipping → weaker TCR signaling and impaired Treg induction, providing a molecular mechanism for Treg deficiency in ITP SRSF1-LCK Treg axis

Synthesis & practical implications (concise)

1) ITP is mechanistically heterogeneous: both peripheral destruction and impaired production are evidenced by human kinetic studies, in vitro megakaryocyte assays, genetic cohorts, and clinical responses to TPO‑RAs and immune therapies BJH 2009 mix mechanisms. 2) Immune dysregulation (autoantibodies, TFH/B cell activation, Treg deficiency, cytotoxic T cells, innate phagocytes) can drive both destruction and production defects; targeting upstream immune pathways can restore platelet production in selected cases (MSC, targeted biologics, pathway-specific drugs) Autoimmunity Reviews mechanistic synthesis.

Limitations, blind spots & uncertainties

• Many cited syntheses are narrative reviews — risk of selective citation and heterogeneity in methods across older and newer studies Autoimmunity Reviews limitations.
• In vitro megakaryocyte suppression assays use progenitors (cord blood/CD34+) that imperfectly replicate adult bone marrow microenvironments; clinical translation requires caution Chang 2003 in vitro limits.
• Genetic/omic target discovery (post-GWAS MR) points to candidate causal genes/proteins but requires cell-type specific validation (platelet vs immune cell eQTLs) and experimental follow-up before therapeutic claims Post-GWAS ITP targets.

Primary citations used (selected)

• Autoimmunity Reviews ITP Pathogenesis
• Chang et al., Blood 2003
• BJH 2009 ITP review
• UC-MSC ITP Thromb Haemost 2012
• Haematologica 2026 genetic-guided therapy
• Post-GWAS ITP targets 2025

If you want: I can (1) generate more fine-grained plots (e.g., forest of autoantibody effects on megakaryopoiesis across studies), (2) produce a cell-type eQTL colocalization figure for candidate genes (DNAJC21/RNF5) using available GWAS/eQTL summary statistics, or (3) build an evidence-weighted network that scores patients by likely dominant mechanism (destruction vs production). Click "Run AI Scientist Analysis" to start automated analyses or use the BGPT graph link below to explore custom graphs.